Global Research Coalition Establishes Rigorous New Protocols to Validate Microbial DNA Presence Within Human Tumors

International researchers led by NUS Medicine propose a best-practices checklist to prevent contamination in cancer microbiome studies and ensure reliable results.

By: AXL Media

Published: Mar 26, 2026, 4:54 AM EDT

Source: Information for this report was sourced from NUS Medicine and A*STAR Genome Institute of Singapore.

The Challenge of the Low-Biomass Haystack

In recent years, the field of oncology has been electrified by studies suggesting that bacteria, fungi, and viruses may reside within tumors, potentially influencing cancer growth and treatment response. However, identifying microbial DNA in human tissue is often described as finding a needle in a haystack. Many organs are traditionally considered microbe-free or contain extremely low amounts of microbial material. According to Associate Professor Niranjan Nagarajan of NUS Medicine, these "low-biomass" samples are exceptionally vulnerable to minute amounts of contamination introduced during surgery, laboratory processing, or even DNA sequencing. Without stringent validation, these external signals can be mistaken for a tumor’s internal microbiome.

Learning from the Evolution of Ancient DNA Research

The research team drew significant parallels between the current state of cancer microbiome studies and the early hurdles faced in ancient DNA research. Decades ago, the study of ancient remains struggled with similar issues of degradation and modern contamination until the field adopted rigorous, standardized protocols. By reviewing recurring methodological failures—such as a heavy reliance on bioinformatics without physical validation—the international coalition argues that the cancer microbiome field must mature into a reliable discipline by implementing equivalent safeguards. This involves moving beyond a single line of evidence toward a multi-faceted approach to biological truth.

A Practical Pipeline for Aseptic Sample Collection

The first pillar of the new recommendations focuses on the point of origin: the operating room. Researchers emphasize that tumor samples must be collected using strict aseptic techniques to minimize the introduction of environmental DNA. A critical component of this protocol is the mandatory use of environmental sampling controls and "matched normal" tissues. By sequencing swabs from the surgical environment alongside the tumor, scientists can effectively subtract "background noise" from their results. This ensures that any detected microbial signatures are geographically and biologically tied to the tumor itself rather than the scalpel or the storage container.